{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:47:37Z","timestamp":1775170057715,"version":"3.50.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/hjh.0b013e32833d4c99","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T09:43:19Z","timestamp":1279791799000},"page":"2329-2335","source":"Crossref","is-referenced-by-count":63,"title":["Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin\u2013angiotensin\u2013aldosterone system"],"prefix":"10.1097","volume":"28","author":[{"given":"Beatriz","family":"Alvarez-Alvarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Abad-Cardiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Fernandez-Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"Martell-Claros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-22-20210208","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R2-22-20210208","first-page":"2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).","volume":"288","year":"2003","journal-title":"JAMA"},{"key":"R3-22-20210208","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","article-title":"High prevalence of primary aldosteronism in the Tayside hypertensive clinic population","volume":"14","author":"Lim","year":"2000","journal-title":"J Hum Hypertens"},{"key":"R4-22-20210208","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","article-title":"Potentially high prevalence of primary aldosteronism in a primary-care population","volume":"353","author":"Lim","year":"1999","journal-title":"Lancet"},{"key":"R5-22-20210208","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study","volume":"48","author":"Lim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R6-22-20210208","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetical correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"key":"R7-22-20210208","first-page":"1633","article-title":"Genetic an\u00e1lisis of aldoterone synthase in patients with idiopathic aldosteronism","volume":"84","author":"Takeda","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-22-20210208","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/00005344-200006000-00017","article-title":"Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension","volume":"35","author":"Stergiou","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"R9-22-20210208","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin\u2013angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"R10-22-20210208","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMcp041698","article-title":"Resistant or difficult to control hypertension","volume":"355","author":"Moser","year":"2006","journal-title":"N Engl J Med"},{"key":"R11-22-20210208","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000081953","article-title":"Effects of combination treatment with Losartan and Trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy","volume":"24","author":"Nakao","year":"2004","journal-title":"Am J Nephrol"},{"key":"R12-22-20210208","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","article-title":"Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data","volume":"48","author":"MacKinnon","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R13-22-20210208","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11906-005-0008-1","article-title":"Aldosterone antagonism: an emerging strategy for effective blood pressure lowering","volume":"7","author":"Pratt-Ubunama","year":"2005","journal-title":"Curr Hyperten Rep"},{"key":"R14-22-20210208","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"},{"key":"R15-22-20210208","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11906-004-0071-z","article-title":"Adding low-dose spironolactone to multidrug regimens for resistant hypertension","volume":"6","author":"Berecek","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"R16-22-20210208","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with resistant hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"key":"R17-22-20210208","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R18-22-20210208","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","article-title":"Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension","volume":"19","author":"Sharabi","year":"2006","journal-title":"Am J Hypertens"},{"key":"R19-22-20210208","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","article-title":"Low-dose spironolactone in the management of resistant hypertension: a surveillance study","volume":"25","author":"Lane","year":"2007","journal-title":"J Hypertens"},{"key":"R20-22-20210208","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"R21-22-20210208","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"R22-22-20210208","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events.","volume":"358","author":"ONTARGET investigators, Yusuf S, Te Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R23-22-20210208","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacc.2008.10.036","article-title":"The sudden demise of dual renin\u2013angiotensin system blockade or the soft science of the surrogate end point","volume":"53","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R25-22-20210208","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0300-8932(04)77129-8","article-title":"Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure","volume":"57","author":"Tamargo","year":"2004","journal-title":"Rev Esp Cardiol"},{"key":"R26-22-20210208","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","article-title":"Aldosterone and refractory hypertension: a prospective cohort study","volume":"19","author":"Sartori","year":"2006","journal-title":"Am J Hypertens"},{"key":"R27-22-20210208","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J Hypertens"},{"key":"R28-22-20210208","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0895-7061(00)01301-7","article-title":"Laragh's lessons for treating hypertension","volume":"14","author":"Laragh","year":"2001","journal-title":"Am J Hypertens"},{"key":"R29-22-20210208","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0895-7061(03)00867-7","article-title":"Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT","volume":"16","author":"Laragh","year":"2003","journal-title":"Am J Hypertens"},{"key":"R30-22-20210208","doi-asserted-by":"crossref","first-page":"40A","DOI":"10.1016\/0002-9149(93)90244-7","article-title":"Dose-related cardiovascular effects of spironolactone","volume":"71","author":"Schohn","year":"1993","journal-title":"Am J Cardiol"},{"key":"R31-22-20210208","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"R32-22-20210208","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/08037050310009950","article-title":"High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension","volume":"12","author":"Martell","year":"2003","journal-title":"Blood Pressure"},{"key":"R33-22-20210208","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11906-006-0038-3","article-title":"Fat tissue metabolism and adrenal steroid secretion","volume":"8","author":"Lamounier-Zepter","year":"2006","journal-title":"Curr Hypertens Rep"},{"key":"R34-22-20210208","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/01.HYP.0000113294.06704.64","article-title":"Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion","volume":"43","author":"Goodfriend","year":"2004","journal-title":"Hypertension"},{"key":"R35-22-20210208","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJM198104163041602","article-title":"The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients","volume":"304","author":"Tuck","year":"1981","journal-title":"N Engl J Med"},{"key":"R36-22-20210208","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.numecd.2008.06.001","article-title":"Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity","volume":"19","author":"Dall'Asta","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R37-22-20210208","first-page":"699","article-title":"Discontinuation on antihypertensives unnecessary before aldosterone screening","volume":"37","author":"Davidson","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R38-22-20210208","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1373\/clinchem.2004.041780","article-title":"Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of the plasma aldosterone concentration to plasma renin activity","volume":"51","author":"Schwartz","year":"2005","journal-title":"Clin Chem"},{"key":"R39-22-20210208","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","article-title":"Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-201011000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T02:05:39Z","timestamp":1618365939000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201011000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e32833d4c99","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}